Global Organoids Market Size By Type (Intestinal Organoid, Hepatic Organoid), By Application (Biopharmaceutical Companies, Contract Research Organizations), By Region, And Segment Forecasts, 2023 to 2...

lobal Organoids Market Report Description

The Global Organoids Market was valued at USD 1.9 billion in 2023 and is projected to surpass USD 6.8 billion by 2031, growing at a CAGR of 17.1% during the forecast period (2023–2031). The market growth is driven by the increasing adoption of organoids for disease modeling, drug discovery, and personalized medicine. Organoids, which are 3D miniaturized and simplified versions of organs, mimic the physiological and genetic features of real human tissues, making them an invaluable tool in biomedical research.

The surge in demand for precision medicine, coupled with the rising burden of chronic and rare diseases, has significantly enhanced the use of organoids in translational research. Furthermore, advancements in stem cell biology, regenerative medicine, and bioengineering have accelerated organoid development, offering promising avenues for pharmaceutical companies, academic research institutions, and clinical laboratories.

Drivers

1. Growing Applications in Drug Discovery & Personalized Medicine

Organoids are increasingly being utilized in preclinical drug testing and personalized treatment planning. They provide a more accurate representation of human tissue response than traditional 2D cell cultures or animal models, reducing the cost and time of drug development.

2. Rising Prevalence of Chronic & Rare Diseases

The growing incidence of cancer, neurodegenerative disorders, and genetic diseases is driving the demand for advanced disease modeling. Cancer organoids, in particular, are gaining attention for tumor-specific drug screening and biomarker discovery.

3. Technological Advancements in Stem Cell Research

Rapid innovations in induced pluripotent stem cell (iPSC) technologies and 3D bioprinting are facilitating organoid development. Automated organoid culture platforms and high-throughput screening systems are further boosting market growth.

Restraints

1. High Cost of Organoid Development

The production and maintenance of organoids require expensive cell culture media, growth factors, and sophisticated laboratory infrastructure, limiting accessibility for smaller research organizations.

2. Lack of Standardization & Ethical Concerns

The absence of standardized protocols for organoid production and ethical concerns regarding their use in human disease modeling pose regulatory and adoption challenges.

Opportunity

1. Expansion of Organoids in Regenerative Medicine

Organoids hold immense potential in regenerative medicine and tissue engineering. They could be used to repair or replace damaged tissues, offering new treatment possibilities for organ failure and genetic disorders.

2. Integration with Artificial Intelligence & High-Throughput Screening

Combining organoid platforms with AI-driven analytics and robotic automation will enhance drug discovery efficiency and precision, opening lucrative opportunities for pharmaceutical R&D.

Market by System Type Insights

Based on system type, Cancer Organoids dominated the market in 2023, accounting for the largest revenue share due to their extensive use in oncology research and precision cancer therapy. However, Brain and Neural Organoids are expected to witness the fastest growth during the forecast period, driven by increasing neurological research and drug testing for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Market by End-use Insights

In terms of end-use, Pharmaceutical & Biotechnology Companies emerged as the largest revenue contributor in 2023, driven by rising demand for organoids in preclinical drug testing and biomarker discovery. Academic & Research Institutes are also anticipated to grow significantly, supported by increasing government and private funding for advanced biomedical research.

Market by Regional Insights

North America dominated the global organoids market in 2023, driven by strong research infrastructure, high investment in drug discovery, and the presence of leading biotechnology firms. Europe held the second-largest share, supported by robust academic research networks and regulatory initiatives promoting advanced therapies.

However, Asia-Pacific is expected to register the highest CAGR during the forecast period, with countries like China, Japan, and South Korea investing heavily in stem cell research, personalized medicine, and precision oncology.

Competitive Scenario

Key players operating in the global organoids market include:

STEMCELL Technologies Inc.

Crown Bioscience Inc.

Hubrecht Organoid Technology (HUB)

DefiniGEN Ltd.

Cellesce Ltd.

MIMETAS BV

PeproTech Inc.

Thermo Fisher Scientific Inc.

These companies are focusing on strategic collaborations, mergers & acquisitions, and product innovations to expand their organoid product portfolios. For example:

In 2023, STEMCELL Technologies launched an advanced liver organoid culture kit for drug metabolism and toxicity testing.

In 2024, MIMETAS partnered with a leading pharma company to develop brain organoids for neurodegenerative disease drug screening.

In 2025, HUB announced a global licensing agreement to commercialize patient-derived tumor organoids for personalized oncology research.

Scope of Work – Global Organoids Market

Key Market Developments

June 2023: Hubrecht Organoid Technology entered a strategic partnership with a European cancer research institute to develop patient-derived tumor organoids for high-throughput drug screening.

January 2024: Thermo Fisher Scientific launched an automated platform for large-scale organoid production to accelerate pharmaceutical research.

March 2025: Crown Bioscience expanded its organoid biobank to include rare tumor models for precision oncology applications.

FAQs

1) What is the current market size of the Global Organoids Market?

The global organoids market was valued at USD 1.9 billion in 2023.

2) What is the major growth driver of the Global Organoids Market?

The major growth driver is the increasing use of organoids in drug discovery, personalized medicine, and disease modeling, particularly for cancer and neurological disorders.

3) Which is the largest region during the forecast period in the Global Organoids Market?

North America is the largest region due to advanced research infrastructure and strong biotech industry presence.

4) Which segment accounted for the largest market share in the Global Organoids Market?

The Cancer Organoids segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Organoids Market?

Key players include STEMCELL Technologies, Crown Bioscience, Hubrecht Organoid Technology, MIMETAS, and Thermo Fisher Scientific.

Would you like me to also create a visually formatted PDF report for the Global Organoids Market with these details? Or should I generate similar reports for other biotech-related markets?